Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Depreciation & Amortization (CF) (2016 - 2025)

Rein Therapeutics filings provide 10 years of Depreciation & Amortization (CF) readings, the most recent being $1000.0 for Q2 2025.

  • For the quarter ending Q2 2025, Depreciation & Amortization (CF) fell 75.0% year-over-year to $1000.0, compared with a TTM value of $1000.0 through Dec 2025, down 98.41%, and an annual FY2025 reading of $1000.0, down 98.41% over the prior year.
  • Depreciation & Amortization (CF) hit $1000.0 in Q2 2025 for Rein Therapeutics, down from $4000.0 in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $59000.0 in Q1 2024, with the low at $1000.0 in Q2 2025.
  • Median Depreciation & Amortization (CF) over the past 5 years was $40000.0 (2021), compared with a mean of $31533.3.
  • The sharpest move saw Depreciation & Amortization (CF) crashed 97.14% in 2021, then soared 1950.0% in 2022.
  • Year by year, Depreciation & Amortization (CF) stood at $40000.0 in 2021, then grew by 7.5% to $43000.0 in 2022, then rose by 20.93% to $52000.0 in 2023, then plummeted by 92.31% to $4000.0 in 2024, then plummeted by 75.0% to $1000.0 in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $1000.0, $4000.0, and $59000.0 for Q2 2025, Q2 2024, and Q1 2024 respectively.